Discovery Labs to Present at the Stifel Nicolaus Healthcare Conference 2012
WARRINGTON, Pa., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, will be presenting at the Stifel Nicolaus Healthcare Conference 2012 on Thursday, September 6, 2012, at 9:45 AM EDT. The conference will be held September 5 - 6, 2012 at the Four Seasons Hotel Boston, in Boston, Massachusetts.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus to create life-saving products for critical care patients with respiratory disease and improve the standard of care for pulmonary medicine. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized and aerosolized formulations. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient, targeted upper-respiratory or alveolar delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com .
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Except as otherwise required by law, Discovery Labs undertakes no obligation to update or revise any forward-looking statements.
CONTACT: Investor Relations LifeSci Advisors LLC - Michael Rice - (646) 597-6979 firstname.lastname@example.org Company John G. Cooper, President and Chief Financial Officer - (215) 488-9490
Source: Discovery Laboratories, Inc. 2012 GlobeNewswire, Inc.